大剂量静脉维生素C降低中度重症急性胰腺炎患者的C反应蛋白水平、液体潴留和APACHE II评分:一项前瞻性、随机、双盲、安慰剂对照研究
该前瞻性、随机、双盲、安慰剂对照试验纳入症状发作72小时内预测为中度重症急性胰腺炎(MSAP)或重症急性胰腺炎(SAP)的成人患者,随机接受维生素C输注(200 mg/kg/24 h)或匹配安慰剂,疗程7天,主要终点为28天死亡率。2019年9月至2023年6月共纳入212例成人(155例MSAP,57例SAP),因28天死亡率低于预期而提前终止。HDIVC组与对照组28天死亡率无差异(3/109 vs. 4/103,未调整OR 0.70,95%CI 0.15-3.21,P=0.647)。在MSAP患者中,HDIVC组C反应蛋白下降更明显(第0-3天中位数72 mg/L vs. 46 mg/L,P=0.003;第0-7天中位数168 mg/L vs. 121 mg/L,P=0.013),液体潴留量更低(第0-1天中位数676.5 ml vs. 1130 ml,P=0.04;第0-2天中位数511 ml vs. 1290 ml,P=0.02;第0-3天中位数692 ml vs. 1534 ml,P=0.04),APACHE II评分第0-7天下降幅度更大(中位数变化3 vs. 2,P=0.01);SAP患者中未观察到显著差异。作者认为这些效应可能与研究药物无直接关系。
要点
- HDIVC未显著降低MSAP和SAP患者28天死亡率(3/109 vs. 4/103,未调整OR 0.70,95%CI 0.15-3.21,P=0.647)。
- MSAP患者中HDIVC组CRP下降更明显(第0-3天中位数72 mg/L vs. 46 mg/L,P=0.003;第0-7天中位数168 mg/L vs. 121 mg/L,P=0.013)。
- MSAP患者中HDIVC组液体潴留量更低(第0-1天中位数676.5 ml vs. 1130 ml,P=0.04;第0-2天中位数511 ml vs. 1290 ml,P=0.02;第0-3天中位数692 ml vs. 1534 ml,P=0.04)。
- MSAP患者中HDIVC组APACHE II评分第0-7天下降幅度更大(中位数变化3 vs. 2,P=0.01)。
- SAP患者中未观察到上述显著差异;作者认为MSAP中的潜在获益可能与研究药物无直接关系。
适用人群与场景
- 症状发作72小时内诊断为预测MSAP或SAP的成人患者。
- 研究纳入212例成人,其中155例MSAP、57例SAP。
处置流程与药物剂量
- 维生素C输注剂量为200 mg/kg/24 h,疗程7天。
- 对照组接受匹配安慰剂。
研究设计与关键结果
- 研究类型:前瞻性、随机、双盲、安慰剂对照试验;2019年9月至2023年6月纳入212例成人(155例MSAP,57例SAP);因28天死亡率低于预期而提前终止。
- 主要终点:28天死亡率HDIVC组3/109 vs. 对照组4/103,未调整OR 0.70,95%CI 0.15-3.21,P=0.647。
- MSAP患者CRP下降:第0-3天中位数72 mg/L vs. 46 mg/L,P=0.003;第0-7天中位数168 mg/L vs. 121 mg/L,P=0.013。
- MSAP患者液体潴留量:第0-1天中位数676.5 ml vs. 1130 ml,P=0.04;第0-2天中位数511 ml vs. 1290 ml,P=0.02;第0-3天中位数692 ml vs. 1534 ml,P=0.04。
- MSAP患者APACHE II评分第0-7天中位数变化3 vs. 2,P=0.01。
- SAP患者中未观察到显著差异。
证据类型、等级与局限
- 证据类型:前瞻性、随机、双盲、安慰剂对照试验。
- 局限:试验因28天死亡率低于预期而提前终止;作者认为MSAP中的潜在获益可能与研究药物无直接关系。
对床旁实践的改变
- 原文结论:HDIVC未显著降低MSAP和SAP患者28天死亡率;MSAP患者中观察到的CRP、液体潴留和APACHE II评分改善可能与研究药物无直接关系,SAP患者中未观察到类似变化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aim of this study was to investigate whether high-dose intravenous vitamin C (HDIVC) could decrease the mortality rate within 28 days among patients moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP).
METHODS: In this randomized, placebo-controlled trial, patients diagnosed with predicted MSAP or SAP within 72 h of symptom onset were enrolled to receive either a vitamin C infusion (200 mg/kg/24 h) or a matched placebo for 7 days. The primary outcome was 28-day mortality.
RESULTS: 212 adults including 155 MSAP and 57 SAP were enrolled from September 2019 to June 2023. The trial was terminated prematurely due to a lower than expected 28-day mortality rate which showed no difference between the HDIVC and Control group (3/109 vs. 4/103, unadjusted OR: 0.70, 95% CI, 0.15-3.21, p = 0.647). Among patients with MSAP, the HDIVC group exhibited a more pronounced reduction in C-reactive protein levels compared to the Control group (Day0 to Day3, median 72 mg/L vs. 46 mg/L, p = 0.003; Day0 to Day7, median 168 mg/L vs. 121 mg/L, p = 0.013); The volume of fluid retention was lower in the HDIVC group compared to the Control group (Day0-Day1, median 676.5 ml vs. 1130 ml, P = 0.04; Day0-Day2, median 511 ml vs. 1290 ml, P = 0.02; Day0-Day3, median 692 ml vs. 1534 ml, P = 0.04). The APACHE II scores reduction from Day0 to Day7 was significantly greater in the HDIVC group in APACHE II scores (median change of 3 vs. 2, P = 0.01). No significant difference was observed among patients with SAP.
CONCLUSION: HDIVC did not significantly reduce 28-day mortality in MSAP and SAP patients. While it showed potential benefits in reducing CRP, fluid retention, and APACHE II scores in MSAP patients, these effects may not be directly related to the study drug, and no similar changes were observed in SAP patients.
TRIAL REGISTRATION: ChiCTR.org.cn, ChiCTR1900022022. Registered March 21 2019, https//www.chictr.org.cn/showproj.html?proj=37,106 .
参考来源
- Zhao B, Sun W, Wang Y, et al. High-dose intravenous vitamin C reduce C-reactive protein levels, fluid retention, and APACHE II scores in patients with moderately severe acute pancreatitis: a prospective, randomized, double-blinded, placebo-controlled study. Ann Intensive Care. 2025. PMID: 40091112. doi:10.1186/s13613-025-01437-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。